Instil Bio, Inc. announced the appointment of Jamie Freedman, M.D., Ph.D., as its new Chief Medical Officer. Dr. Freedman brings over 20 years of leadership experience in biopharmaceutical research and development, with a focus on oncology drug development.
Her career includes executive roles at major pharmaceutical companies such as Genentech, AstraZeneca, GSK, and Merck. Dr. Freedman has been instrumental in achieving 15 drug approvals and successful launches across various therapeutic areas.
This key appointment is expected to be a significant asset in advancing AXN-2510, Instil's lead PD-L1xVEGF bispecific antibody program. Her expertise in navigating clinical development, regulatory approval, and commercialization is crucial for the company's strategic goals in solid tumors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.